Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts

NCT06491446 is registered in ClinicalTrials.gov with Antiva Biosciences as lead sponsor.

NCT NCT06491446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06491446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts
Lead sponsor
Antiva Biosciences
Phase
Phase 1/2
Overall status
Completed
Start date
March 27, 2024
Completion date
April 20, 2026
Enrollment
141 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection